Gender Care in the United Kingdom
The United Kingdom was the first major Western healthcare system to openly move away from the gender-affirmative model for minors. After the interim report of the Cass Review, NHS England closed the Tavistock GIDS clinic in March 2024, puberty blockers could from then on only be prescribed within research, and the entire care pathway for young people with gender dysphoria was restructured. The UK approach is now the international benchmark for an evidence-based reorientation.
Read more about this on this site: NICE review (UK, 2020), NICE, NHS England and BBC — NHS to close Tavistock child gender identity clinic (2022).
Tavistock and the downfall of GIDS
The Gender Identity Development Service (GIDS), based at the Tavistock and Portman NHS Foundation Trust in London, was for nearly thirty years the only NHS centre providing gender care to minors in England and Wales. During the 2010s, the number of referrals surged—from a few dozen to more than 5,000 a year—with a striking overrepresentation of adolescent girls and young people with autism or comorbid mental health problems.
From 2018 onward, clinicians successively came forward with serious concerns: psychotherapist David Bell (Tavistock Governor), psychologists Anna Hutchinson and Marcus Evans, and clinical advisor Sue Evans. They described a culture in which the gender-affirmative approach was applied hastily, comorbidities were ignored, and critical questions were discouraged internally. In early 2021, the Care Quality Commission rated GIDS as 'inadequate'. NHS England announced its closure in 2022. The clinic was permanently shut down in March 2024.
Bell vs Tavistock
The case Bell vs Tavistock (2020) was a turning point in the British debate. Detransitioner Keira Bell, who received puberty blockers and cross-sex hormones through GIDS as a teenager and later underwent a mastectomy, brought legal proceedings against Tavistock. The High Court ruled that it was highly unlikely that children aged 13 or under, and very doubtful that 14- and 15-year-olds, could fully understand the consequences of puberty suppression and give 'Gillick-competent' consent. On appeal, the ruling was overturned on procedural grounds, but the case gave the debate extra weight; the Cass Review had already been commissioned in September 2020. Bell herself became a prominent voice in the debate on detransition.
The Cass Review and the NHS shift
In 2020, NHS England commissioned an independent review led by paediatrician Dr Hilary Cass. The final report (April 2024) concluded, based on systematic literature reviews by the University of York, that the evidence base for puberty suppression and cross-sex hormones in minors is 'remarkably weak'. NHS England fully adopted the recommendations and published the official response. An extensive discussion is available on the Cass Review page.
Ban on puberty blockers
The British government announced that the ban on puberty blockers for clinical use in minors with gender dysphoria would apply indefinitely—see the British government announcement. The decision is based on advice from the Commission on Human Medicines and the Cass Review. Prescriptions are now permitted only as part of a strictly controlled clinical research protocol (the PATHWAYS study). In 2026, a British judge rejected a legal challenge to the trial; see the report on the puberty blocker trial involving 226 children and the discussion on puberteitsblokkers.nl. Private clinics and online providers are also prohibited from supplying puberty blockers to minors. The ban applies to both new and existing patients who had not yet started treatment.
New regional centres
Instead of a single specialised clinic, NHS England now operates regional centres that take a holistic approach: mental healthcare comes first, rather than medical transition. Comorbid conditions—including autism spectrum conditions, trauma, eating disorders and depression—are systematically assessed before a gender diagnosis is made. Cross-sex hormones are not available to those under 16; between the ages of 16 and 18, they are available only with 'extreme caution' and following extensive multidisciplinary assessment. In 2026, NHS England went a step further and paused new referrals of 16- and 17-year-olds for cross-sex hormones in March.
WPATH Files and British involvement
In March 2024, the WPATH Files were released: leaked internal messages and recordings from the World Professional Association for Transgender Health about doubts within the organisation. That WPATH suppressed its own systematic reviews at Johns Hopkins when the findings were unfavourable emerged in June 2024 from documents in a US court case. British researchers, including Cass herself, have publicly cited this as evidence that the international guidelines on which the original English policy was based were not developed independently.
The situation in Scotland, Wales and Northern Ireland
The NHS is devolved. In 2024, Scotland (NHS Scotland) brought the Sandyford clinic largely into line with the Cass recommendations and paused new prescriptions for puberty blockers. Wales is following English policy; NHS Wales later also suspended new referrals for gender surgery, as genderzorgnederland.nl describes. Northern Ireland had already been referring patients to GIDS for some time and has therefore automatically adopted the NHS England shift.
Gender recognition and legislation
Separate from medical care, legal gender recognition in the UK is governed by the Gender Recognition Act 2004. An attempt by the Scottish government to introduce self-identification was blocked by the British government in 2023, citing the implications for sex-based rights. The UK Supreme Court ruled in April 2025 that 'woman' in the Equality Act refers to biological sex—a judgment with major implications for sport, shelters and prisons.